Novel cell therapy developer Waypoint Bio has secured USD 14.5 million in a seed funding round led by Hummingbird Ventures, with participation from Recode Ventures and Fifty Years.
The firm plans to allocate funds to develop CAR T-cell therapies that exhibit efficacy against tumor microenvironments, using in vivo spatial pooled screening technology. Successively, the company will focus on developing Treg therapies targeting autoimmune diseases.
Waypoint Bio is a biotechnology company that develops cell therapies for solid tumors. The company's proprietary platform integrates high-resolution spatial biology with pooled screening techniques, allowing rapid and accurate in vivo testing. This approach enables the evaluation of cell therapies in three-dimensional tissue environments, addressing the complexities of solid tumor microenvironments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.